Back to today’s briefing

Story perspectives

Esketamine: Fast Relief for Treatment-Resistant Depression

11/8/2025

23 5

Summary

Story summary

Esketamine, a ketamine-derived nasal spray, was approved by Johnson & Johnson in 2019 to treat treatment-resistant depression (TRD) in patients not responding to at least two standard treatments.
It can provide rapid relief.
The effects are not permanent.
Maintenance treatments are needed.
Hudson Valley Ketamine Lounge emphasizes a supportive environment for infusions.

1 of 1

Story summary

Esketamine, a ketamine-derived nasal spray, was approved by Johnson & Johnson in 2019 to treat treatment-resistant depression (TRD) in patients not responding to at least two standard treatments.
It can provide rapid relief.
The effects are not permanent.
Maintenance treatments are needed.
Hudson Valley Ketamine Lounge emphasizes a supportive environment for infusions.